Allstocks.com's Bulletin Board Post New Topic  Post A Reply
my profile login | register | search | faq | forum home

  next oldest topic   next newest topic
» Allstocks.com's Bulletin Board » Asia, China and Canadian Stocks » TMC ...more good news

 - UBBFriend: Email this page to someone!    
Author Topic: TMC ...more good news
TradingWizard
Member


Icon 6 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Tm Bioscience Signs Supply Agreement with Pharmacogenetics Diagnostic Laboratory


TORONTO, Apr 29, 2004 /PRNewswire-FirstCall via COMTEX/ -- (PR NewsWire)


Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), an emerging leader in DNA-based diagnostic testing, announced today that it has entered into a two-year contract with the Pharmacogenetics Diagnostic Laboratory (PGx) of the University of Louisville Medical School to supply it with the Tag-It(TM) P450-2D6 Mutation Detection Kit. This kit identifies the presence or absence of important mutations common in patients with atypical drug metabolism, which can lead to adverse drug reactions (ADRs).

ADRs have been cited as one of the leading causes of death in the US[1]. Scientists estimate that P450-2D6-derived enzymes metabolize 20% of currently available prescription drugs. The Tag-It(TM) Mutation Detection Kit for P450- 2D6 provides simultaneous detection of 12 mutations (24 alleles) and two gene rearrangements in a multiplex format. The Tag-It(TM) P450-2D6 kit is a cost effective, high throughput assay that will improve the productivity of the pharmacogenetic lab.

"PGx is one of the leading laboratories for pharmacogenetic testing, and we are pleased that our Tag-It(TM) P450-2D6 test meets the high standards of their scientists and laboratorians," stated Greg Hines, CEO of Tm Bioscience. "This contract further validates the growing market for P450 testing and is in line with Tm's strategy to focus on customers dedicated to bringing P450 testing into the mainstream of laboratory practice."

"Currently, the assessment of drug metabolism mutations is frequently done through laboratory developed tests, which are not particularly accurate and have become increasingly less efficient as the volume of testing continues to rise," explained PGx Lab's Assistant Director, Mark Linder, PhD, DABCC, FACB. "The Tm Bioscience kit accurately detects mutations in the key alleles known to affect drug metabolism, providing both clinicians and physicians with critical information that they will be able to use in developing better tools for patient management."

1. JAMA 1998; 279:1200-1205

About Tag-It(TM) genetic tests

Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has already commercialized a series of Tag-It(TM) tests for coagulation genes, launched in December 2002; the Tag-It(TM) P450-2D6 test, first in a series of tests for drug metabolism genes; and the Tag-It(TM) CFTR 40+4 test, launched in September 2003. The Company's pre-commercial pipeline includes the Tag-It(TM) P450-2C9 and P450- 2C19 drug metabolism gene tests and an Ashkenazi Jewish panel combining several common hereditary disease gene tests. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a bead based instrument growing in popularity. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, highly accurate, high- throughput, low-cost DNA-based tests.

About Tm Bioscience - Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.

About the Pharmacogenetics Diagnostic Laboratory

The Pharmacognetic Diagnostic Laboratory (PGx Lab) at the University of Louisville School of Medicine focuses on the study of the ways in which genetics affects medications. This scientific data provides caregivers the most accurate and timely pharmacogenetic tests and information possible to allow them to radically decrease the risk of adverse drug reactions. The staff has more than 45 years of experience in scientific research and clinical medicine. Additional information on the PGx Lab can be found at www.pgxlab.com.

INVESTOR RELATIONS CONTACTS: Equicom Group Contact (Canada): Euro RSCG Life NRP Contact (U.S.): James Smith Sharon Weinstein The Equicom Group Account Supervisor Euro RSCG Life NRP Tel.: 416-815-0700 Tel.: 212-845-4271 Fax: 416-815-0080 Fax: 212-845-4260 Email: jsmith@equicomgroup.com Email: sharon.weinstein@eurorscg.com

SOURCE Tm Bioscience Corporation

James Smith, The Equicom Group, +1-416-815-0700, fax, +1-416-815-0080, jsmith@equicomgroup.com; or Sharon Weinstein, Account Supervisor, Euro RSCG Life NRP, +1-212-845-4271, fax, +1-212-845-4260, sharon.weinstein@eurorscg.com, both for Tm Bioscience Corporation

http://www.tmbioscience.com



Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
GREGDOGG
Member


Rate Member
Icon 6 posted      Profile for GREGDOGG     Send New Private Message       Edit/Delete Post   Reply With Quote 
Heyyy Wizard, Great pick, .68 looks like a decent entry.
Posts: 1171 | From: B.C. CANADA | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Tm Bioscience Notice of Conference Call


TORONTO, May 06, 2004 (Canada NewsWire via COMTEX) -- (Canada NewsWire)


Tm Bioscience Corporation (TSX: TMC) will be holding a conference call to discuss its first quarter financial results. Mr. Greg Hines, President and Chief Executive Officer and Mr. Jim Pelot, Chief Financial Officer, will be hosting the call.

DATE: Tuesday, May 11, 2004

TIME: 4:30 pm, Eastern Standard Time

WEBCAST: A live audio webcast of the call will be available at www.tmbioscience.com and www.financialdisclosure.ca.

Webcast attendees are welcome to listen to the conference in real-time or on-demand at your convenience. The webcast will be archived for 90 days.

Please connect to this website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be needed to hear the webcast.

About Tm Bioscience - Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, toxicology and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.

VIEW ADDITIONAL COMPANY-SPECIFIC INFORMATION: http://www.newswire.ca/en/releases/orgDisplay.cgi?okey=75885



Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Today on Canada's Business Report...The Outlook For Profits At Tm Bioscience Corporation
TORONTO, May 7 /CNW/ - On today's edition of Canada's Business Report,
host Robert Graham speaks with Greg Hines, President and CEO Tm Bioscience.
They discuss the company's DNA-based diagnostic testing products, the
huge market for its lead product that tests for cystic fibrosis, the company's
move from the Venture Exchange to the Toronto Stock Exchange, and its
commercial strategy for generating profits.
Hines says, "Our current business plan forecasts the company will reach
profitability by either the fourth-quarter of this year - on a
quarter-over-quarter basis - or at the latest, by the first-quarter of next
year. We have more than enough cash against our current business plan that we
don't need to finance."
Executive produced by Canada NewsWire, Canada's Business Report is the
most comprehensive daily business news program on radio in Canada. With a
focus on the stock markets, investing strategies, corporate developments, and
the health of our economy, the nationally syndicated half-hour program is
heard Monday through Friday, live at 5:06 p.m. ET at http://www.newswire.ca/en/cbr/index.cgi and on the following stations.

ONTARIO
Hamilton CHML AM 900 - 5:30 p.m. ET
London CFPL AM (Radio 98) - 5:30 p.m. ET, Repeat @ 10:00 p.m. ET
Owen Sound - CFOS 560 - 5:30 p.m. ET

MANITOBA
Winnipeg - CJOB 680 - 5:30 p.m. CT

SASKATCHEWAN
Regina - CJME 980 - 7:00 p.m. CT, Repeat @ 5:00 a.m. CT
Saskatoon - CKOM 650 - 7:00 p.m. CT, Repeat @ 5:00 a.m. CT

ALBERTA
Calgary - CHQR AM 770 - 6:30 p.m. MT

BRITISH COLUMBIA
Kelowna - CKOV 63 AM Radio - 6:05 p.m. PT.



Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Tm Bioscience reports first quarter results


TORONTO, May 11, 2004 (Canada NewsWire via COMTEX) -- (Canada NewsWire)


Tm Bioscience Corporation (TSX: TMC), an emerging leader in DNA-based diagnostic testing, today announced its financial and operational results for the first quarter ended March 31, 2004.

For the first quarter, the Company recognized revenue of $878,301 compared with $775,265 for the fourth quarter of 2003 and $329,501 for the third quarter of 2003, the first period for which the Company recorded product revenue. Revenue for the first quarter of 2004 included: $828,132 from the sale of the Company's six commercially available genetic test products; $34,885 in royalty revenue from the sale of Universal Array beads by Luminex; and $15,284 as a pro-rata recognition of a milestone payment received from Luminex related to the commercial availability of their Tm100 based Universal Array Microspheres.

More than 24,000 tests were sold in the first quarter of 2004, compared with 20,000 tests in the fourth quarter of 2003. The Company has and will increase production capacity during the first half of the year in anticipation of second half product demand. The increased capacity which is not yet required for inventory build contributed to the quarter's decreased margins relative to the fourth quarter of 2003. We anticipate that gross margins for the year overall will approach 60%.

"During the quarter we continued invest in the expansion of our product pipeline while advancing our existing product offering through the sales, evaluation and validation process with key accounts," said Greg Hines, President and CEO of Tm Bioscience. "Approximately 20 laboratories have agreed to product evaluations with an interest to convert to our product menu."

For the first quarter ended March 31, 2004 Tm Bioscience reported a net loss of $2,076,962 ($0.01) per share, compared with a net loss of $2,121,122 or ($0.02) per share, for the corresponding period in 2003. For the first quarter, total expenses were $2,858,820 compared with $1,871,137 for the same period in 2003.

Net interest expense decreased $152,826 in the first quarter of 2004 compared with the same period in 2003 reflecting interest income earned on cash, cash equivalents and short-term investments resulting from the Company's financing that concluded on December 22, 2003. Depreciation was $180,224 and $109,267 for the quarters ended March 31, 2004 and 2003 respectively, reflecting an increase of some 65%. This increase corresponds to the capital expenditures related to the build-out and operationalization of the Company's manufacturing, quality control and product development facilities, as well as the leasehold improvements associated with the Company's expanded premises.

Working capital at March 31, 2004 was $7,187,771 including cash, cash equivalents and short term investments of $8,010,550, compared with $9,614,305 and $10,764,909 respectively as at December 31, 2003. The Company had 1,588,750 warrants, compensation options and employee stock options exercised in the quarter, realizing cash of receipts of $446,704.

In conjunction with the quarterly loss, increases in inventory balances comprised a significant portion of the working capital reduction with inventory growing to $2,028,487 from $1,099,579 from year-end 2003. The largest category of inventory growth was in raw materials which were increased to meet forecast product demand and realize manufacturing efficiencies through the latter part of 2004.

The Company expects that cash use from operations will decrease over 2004 reflecting the impact of growing revenue and that further funding prior to achieving profitability will not be required in its current business model.

Operational Highlights

During the first quarter, the Company achieved the following key objectives:

- Continuing revenue momentum through sales of the Company's products.

- Securing ASR status on the Company's CFTR 40 + 4 reagents

- Graduating to the Toronto Stock Exchange

- Launching a direct sales force in the U.S.

- Initiating evaluation activities for its products with a number of potential customers.

- Scaling manufacturing processes to accommodate forecast product demand.

- Establishing a technical services group to provide after sales support and pre-contract technical validation support to potential customers

The Company was provided recognition by two external organizations in the quarter. In the U.S., the Company received an award from market research firm Frost and Sullivan for its CFTR 40 + 4 cystic fibrosis gene detection test. The award recognized the Company as having the "Clinical Diagnostics Product of the Year". In February, the Company received an award from the Canadian Institute for Investor Relations (CIRI) resulting from a poll of institutional investors across Canada that recognized Tm Bioscience for "Best Investor Relations for a TSX-Venture Listed Company".

Notice of Conference Call

Tm Bioscience will be holding a conference call on May 11, 2004 at 4:30pm (EST) where Mr. Greg Hines, President and CEO, and Mr. Jim Pelot, CFO, will discuss the Company's first quarter 2004 results. A live audio webcast of the call will be available at www.financialdisclosure.ca and www.tmbioscience.com. Webcast attendees are welcome to listen to the conference in real-time or on-demand at their convenience. A replay of the call will be archived at those sites for 90 days.

Notice of Annual General Meeting

Tm Bioscience will be holding its Annual General Meeting of Shareholders at 10:00am on June 2nd, 2004 at the TSX Conference Center, 130 King St. W. Toronto, Ontario.

About Tm Bioscience - Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.



Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
I consider this a good holding stock. Nice steady growth.

Tm Bioscience augments Scientific Advisory Board


TORONTO, May 27, 2004 (Canada NewsWire via COMTEX) -- (Canada NewsWire)


Tm Bioscience Corporation (TSX: TMC), an emerging leader in DNA-based diagnostic testing, today announced the appointment of Dr. James Mahony to the Company's Scientific Advisory Board (SAB), effective immediately. The SAB meets regularly to advise management on the selection and development of new DNA-based diagnostic products and provide recommendations on regulatory and commercialization strategies for the Company's growing menu of genetic tests.

"Dr. Mahony is a world leader in developing testing methodology for virology and microbiology and has a solid reputation in the field of infectious disease discovery and laboratory methods," said Greg Hines, President and CEO of Tm Bioscience. "We are grateful to have secured such expertise as we expand our product development focus to include infectious disease testing, one of the largest market opportunities for DNA based diagnostics. We have identified several opportunities using our Universal Array technology that could result in products which more rapidly and cost effectively identify and characterize infectious disease organisms in a clinical setting, leading to improved treatment responses."

Dr. Mahony is currently the Director of the McMaster University Regional Virology and Chlamydiology Laboratory at St. Joseph's Healthcare in Hamilton and is a Professor in the Department of Pathology and Molecular Medicine, McMaster University and on the Special Professional Staff of the Hamilton Health Sciences Corporation. He is a member of numerous professional organizations including the Canadian Society of Microbiologists, the Canadian Association of Clinical Microbiology and Infectious Diseases, is a Fellow of the American Academy of Microbiology, and serves on the Editorial Boards of several journals. He was recently elected President of the Pan American Society for Clinical Virology. Dr. Mahony obtained a Ph.D. in Molecular Biology from the University of Toronto in 1978 and has authored over 160 peer-reviewed publications.

About Tm Bioscience - Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.


------------------
'Alone we can do so little; together we can do so much.' - Helen Keller


Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 14 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Tm Bioscience Adds Two New Cytochrome P450 (CYP) Mutation Detection Kits to Its Pharmacogenomics Product Menu


TORONTO, Jun 01, 2004 /PRNewswire-FirstCall via Comtex/ -- (PR NewsWire)


Tm Bioscience Corporation (Toronto, Ontario; TSX: TMC), an emerging leader in the commercial genetic testing market, today announced the launch of two new Tag-It(TM) Mutation Detection Kits for the P450-2C9 and P450-2C19 genes. These kits identify the presence or absence of important mutations in liver enzymes that are common in patients with atypical drug metabolism, which can lead to adverse drug reactions (ADRs), a leading cause of death in the US. According to the U.S. Food and Drug Administration (FDA), ADRs are responsible for $136 billion in annual healthcare costs, which is greater than the total cost for either cardiovascular or diabetic care.

"As a leading provider of clinical mutation detection kits, Tm Bioscience is focused on offering its customers a comprehensive suite of toxicology tests that are at the forefront of the new revolution in healthcare," stated Greg Hines, CEO. "Cytochrome P450 testing is key to detecting mutations in genes known to affect drug metabolism. These latest products, in concert with our already marketed Tag-It P450-2D6 mutation detection kit, provide clinical laboratories with the ability to efficiently and accurately test for 26 critical mutations affecting drug metabolism, which, we believe, will ultimately improve patient care."

Scientists estimate that 90% of currently available prescription drugs are metabolized by P450-derived enzymes. The Tag-It(TM) suite of P450 kits is a cost-effective, high-quality solution that provides laboratories with a predictive tool to evaluate possible adverse drug reactions. The Tag-It(TM) Mutation Detection Kit for P450-2C9 provides simultaneous detection of 5 different mutations of Cytochrome P450 in a multiplex format, and the Tag-It(TM) Detection Kit for P450-2C19 provides simultaneous detection of 7 mutations in a multiplex format. Multiplexing enables laboratories to simultaneously test patients for numerous mutations, providing broad information to physicians involved in pharmacogenomics.

About Phamacogenomics

Pharmacogenomic testing is rapidly becoming a part of responsible medical practice. It gives physicians the ability to know in advance how a patient will metabolize prescribed medications, reducing the risk of ADRs and making it possible to prescribe the right dose for maximum therapeutic effect the first time.

About Tag-It(TM) genetic tests

Tm Bioscience's product menu is focused in the fields of human genetic disorders, pharmacogenetics and infectious disease. The Company has already commercialized a series of Tag-It(TM) tests for coagulation genes, launched in December 2002; the Tag-It(TM) P450-2D6 test, first in a series of tests for drug metabolism genes; and the Tag-It(TM) CFTR 40+4 test, launched in September 2003. The Company's pre-commercial pipeline includes an Ashkenazi Jewish panel combining several common hereditary disease gene tests. All genetic tests from Tm Bioscience are based on the Tag-It(TM) Universal Array platform, which utilizes a proprietary universal tag system that allows for easy optimization, product development and expansion. Assays from Tm operate on the Luminex xMAP(R) system, a bead based instrument growing in popularity. Combined, the Universal Array and Luminex instrument enable the rapid production of flexible, highly accurate, high-throughput, low-cost DNA-based tests.

About Tm Bioscience -- Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at http://www.tmbioscience.com.

INVESTOR RELATIONS CONTACTS: Equicom Group Contact (Canada): Euro RSCG Life NRP Contact (U.S.): James Smith Sharon Weinstein The Equicom Group Account Supervisor Euro RSCG Life NRP Tel.: 416-815-0700 Tel.: 212-845-4271 Fax: 416-815-0080 Fax: 212-845-4260 Email: jsmith@equicomgroup.com Email: sharon.weinstein@eurorscg.com

SOURCE Tm Bioscience Corporation

James Smith of The Equicom Group, +1-416-815-0700, Fax: +1-416-815-0080, jsmith@equicomgroup.com; or Sharon Weinstein, Account Supervisor of Euro RSCG Life NRP, +1-212-845-4271, Fax: +1-212-845-4260, or sharon.weinstein@eurorscg.com, for Tm Bioscience Corporation


------------------
'Alone we can do so little; together we can do so much.' - Helen Keller


Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
Tm Bioscience notice of annual and special meeting of shareholders


TORONTO, Jun 01, 2004 (Canada NewsWire via COMTEX) -- (Canada NewsWire)


Tm Bioscience Corporation (TSX: TMC), an emerging leader in DNA-based diagnostic testing, will hold its Annual and Special Meeting of Shareholders on Wednesday, June 2, 2004 at 10:00 a.m. at the TSX Conference Centre, 130 King St. W. Toronto, Ontario.

Mr. Greg Hines, President and Chief Executive Officer of Tm Bioscience and Mr. Jim Pelot, Chief Financial Officer, will review the achievements of the past year and present the Company's strategy and vision for the future. Dr. Brad Popovich, Chairman of the Scientific Advisory Board will give a brief presentation on the future of genetic testing and Dr. James Mahony, member of the Scientific Advisory Board, will highlight genetic testing opportunities in the infectious disease arena.

An archived audio webcast of the meeting will be available at www.tmbioscience.com and www.financialdisclosure.ca.

About Tm Bioscience - Putting the Human Genome to Work(TM)

Tm Bioscience is a DNA-based diagnostics company developing a suite of genetic tests. Tm Bioscience's product pipeline includes tests for genetic mutations related to hematology, cystic fibrosis, drug metabolism and other debilitating genetic disorders. Tm Bioscience is located in Toronto, Ontario. Additional information about Tm Bioscience can be found at www.tmbioscience.com.


------------------
'Alone we can do so little; together we can do so much.' - Helen Keller


Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
TradingWizard
Member


Icon 12 posted      Profile for TradingWizard         Edit/Delete Post   Reply With Quote 
TMC is now over $2.5 pps after share consolidation. I almost had a heart attack,because I made a profit of 20,000 forgetting this news:

Tm Bioscience Completes Share Consolidation

TORONTO, Jun 21, 2004 (Canada NewsWire via COMTEX) -- (Canada NewsWire)


Tm Bioscience Corporation (TSX: TMC) today announced the completion of the consolidation of its issued and outstanding common shares on the basis of one (1) post-consolidation share for every five (5) pre-consolidation common shares.

"The common share consolidation, which follows our recently announced graduation to the TSX on April 12th, is another significant step forward in our Company's strategic evolution from a junior technology issuer to an established commercial enterprise," said Jim Pelot, Chief Financial Officer of Tm BioScience.

Tm Bioscience shareholders approved the consolidation of shares at the Company's annual and special meeting of shareholders held on June 2, 2004. All materials necessary to effect the share consolidation have been filed with the Toronto Stock Exchange (TSX) and trading of the Company's common shares on a consolidated basis is expected to commence on the TSX on Friday, June 25, 2004. The common shares of the Company will continue to trade under the symbol "TMC".

Letters of transmittal describing the details of the consolidation and the process by which to obtain share certificates representing the consolidated common shares are expected to be mailed out to registered shareholders of the Company on Tuesday, June 22, 2004. Registered shareholders may also obtain copies of the letter of transmittal by contacting their brokers or the Company's transfer agent, CIBC Mellon Trust Company.

Shareholders of Tm Bioscience who hold their shares through their broker or other intermediary and do not have actual share certificates registered in their name will not be required to complete and return a letter of transmittal. Any pre-consolidation common shares owned by such shareholders will automatically be adjusted as a result of the consolidation to reflect the applicable number of post-consolidation common shares owned by them and no further action is required to be taken by such shareholders. If as a result of the consolidation a shareholder becomes entitled to a fractional share, such fractions will be rounded down to the nearest whole number.

------------------
'Alone we can do so little; together we can do so much.' - Helen Keller


Posts: 1021 | From: Canada | Registered: Feb 2004  |  IP: Logged | Report this post to a Moderator
   

Quick Reply
Message:

HTML is not enabled.
UBB Code™ is enabled.

Instant Graemlins
   


Post New Topic  Post A Reply Close Topic   Feature Topic   Move Topic   Delete Topic next oldest topic   next newest topic
 - Printer-friendly view of this topic
Hop To:


Contact Us | Allstocks.com Message Board Home

© 1997 - 2013 Allstocks.com. All rights reserved.

Powered by Infopop Corporation
UBB.classic™ 6.7.2

Share